BACKGROUND: Ebola virus (EBOV) epidemics pose a major public health risk. There currently is no licensed human vaccine against EBOV. The safety and immunogenicity of a recombinant EBOV glycoprotein (GP) nanoparticle vaccine formulated with or without Matrix-M adjuvant were evaluated to support vaccine development. METHODS: A phase 1, placebo-controlled, dose-escalation trial was conducted in 230 healthy adults to evaluate 4 EBOV GP antigen doses as single- or 2-dose regimens with or without adjuvant. Safety and immunogenicity were assessed through 1-year postdosing. RESULTS: All EBOV GP vaccine formulations were well tolerated. Receipt of 2 doses of EBOV GP with adjuvant showed a rapid increase in anti-EBOV GP immunoglobulin G titers with peak titers observed on Day 35 representing 498- to 754-fold increases from baseline; no evidence of an antigen dose response was observed. Serum EBOV-neutralizing and binding antibodies using wild-type Zaire EBOV (ZEBOV) or pseudovirion assays were 3- to 9-fold higher among recipients of 2-dose EBOV GP with adjuvant, compared with placebo on Day 35, which persisted through 1 year. CONCLUSIONS:Ebola virus GP vaccine with Matrix-M adjuvant is well tolerated and elicits a robust and persistent immune response. These data suggest that further development of this candidate vaccine for prevention of EBOV disease is warranted.
RCT Entities:
BACKGROUND:Ebola virus (EBOV) epidemics pose a major public health risk. There currently is no licensed human vaccine against EBOV. The safety and immunogenicity of a recombinant EBOV glycoprotein (GP) nanoparticle vaccine formulated with or without Matrix-M adjuvant were evaluated to support vaccine development. METHODS: A phase 1, placebo-controlled, dose-escalation trial was conducted in 230 healthy adults to evaluate 4 EBOV GP antigen doses as single- or 2-dose regimens with or without adjuvant. Safety and immunogenicity were assessed through 1-year postdosing. RESULTS: All EBOV GP vaccine formulations were well tolerated. Receipt of 2 doses of EBOV GP with adjuvant showed a rapid increase in anti-EBOV GP immunoglobulin G titers with peak titers observed on Day 35 representing 498- to 754-fold increases from baseline; no evidence of an antigen dose response was observed. Serum EBOV-neutralizing and binding antibodies using wild-type Zaire EBOV (ZEBOV) or pseudovirion assays were 3- to 9-fold higher among recipients of 2-dose EBOV GP with adjuvant, compared with placebo on Day 35, which persisted through 1 year. CONCLUSIONS:Ebola virus GP vaccine with Matrix-M adjuvant is well tolerated and elicits a robust and persistent immune response. These data suggest that further development of this candidate vaccine for prevention of EBOV disease is warranted.
Authors: Kostlend Mara; Meiling Dai; Aaron M Brice; Marina R Alexander; Leon Tribolet; Daniel S Layton; Andrew G D Bean Journal: Vaccines (Basel) Date: 2021-01-17
Authors: Jing-Hui Tian; Nita Patel; Robert Haupt; Haixia Zhou; Stuart Weston; Holly Hammond; James Logue; Alyse D Portnoff; James Norton; Mimi Guebre-Xabier; Bin Zhou; Kelsey Jacobson; Sonia Maciejewski; Rafia Khatoon; Malgorzata Wisniewska; Will Moffitt; Stefanie Kluepfel-Stahl; Betty Ekechukwu; James Papin; Sarathi Boddapati; C Jason Wong; Pedro A Piedra; Matthew B Frieman; Michael J Massare; Louis Fries; Karin Lövgren Bengtsson; Linda Stertman; Larry Ellingsworth; Gregory Glenn; Gale Smith Journal: Nat Commun Date: 2021-01-14 Impact factor: 14.919
Authors: Benjamin J Read; Lori Won; John C Kraft; Isaac Sappington; Aereas Aung; Shengwei Wu; Julia Bals; Chengbo Chen; Kelly K Lee; Daniel Lingwood; Neil P King; Darrell J Irvine Journal: Cell Rep Date: 2022-01-11 Impact factor: 9.423
Authors: Neil Formica; Raburn Mallory; Gary Albert; Michelle Robinson; Joyce S Plested; Iksung Cho; Andreana Robertson; Filip Dubovsky; Gregory M Glenn Journal: PLoS Med Date: 2021-10-01 Impact factor: 11.069